Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours

Summary

To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.

Timeline

Start

2008-01

Primary completion

2010-07

Completion

2014-01

Publications

• van Herpen CM, Lassen U, Desar IM, Brown KH, Marotti M, de Jonge MJ. Pharmacokinetics and tolerability of cediranib, a potent VEGF signalling inhibitor, in cancer patients with hepatic impairment. Anticancer Drugs. 2013 Feb;24(2):204-11. doi: 10.1097/CAD.0b013e32835bd1d2.

Drugs

Indications